For individuals grappling with uncontrolled asthma, a common questionnaire used to assess symptom severity – the Asthma Control Questionnaire-5, or ACQ-5 – proves effective at identifying overt airflow limitation, but falls short in detecting more subtle airway issues. New research published in BMC Pulmonary Medicine highlights the tool’s strengths and limitations, offering a more nuanced understanding of how to assess and manage this chronic respiratory condition. Understanding these nuances is crucial, as asthma affects an estimated 25 million Americans, according to the Centers for Disease Control and Prevention .
The study, conducted in Japan, focused on adults newly diagnosed with uncontrolled asthma who hadn’t yet begun treatment. Researchers aimed to determine how well the ACQ-5 correlated with different patterns of airflow limitation and the presence of type 2 (T2) inflammation, a key driver of asthma symptoms. This is particularly important because asthma isn’t a single disease; it manifests differently in different people, and identifying these variations is key to personalized treatment.
The investigation revealed that the ACQ-5 effectively pinpointed cases of significant airflow limitation – where the lungs struggle to move air in and out – but struggled to identify isolated small airway dysfunction (iSAD) and high-intensity T2 inflammation. The study involved 171 patients with a median age of 46, roughly half of whom were female. Participants completed the ACQ-5, and their lung function was assessed through spirometry, a common pulmonary function test. Researchers then categorized patients based on their airflow patterns: normal lung function, iSAD, or airflow limitation.
ACQ-5 Scores Correlate with Airflow, But Not Subtle Changes
The analysis showed a clear link between higher ACQ-5 scores – indicating worse symptom control – and the presence of airflow limitation. Patients with airflow limitation consistently reported more severe symptoms and had significantly higher ACQ-5 scores compared to those with normal lung function or iSAD (P < .001). The ACQ-5 score demonstrated a moderate negative correlation with key lung function measurements, including forced expiratory flow between 25% and 75% of forced vital capacity (FEF25-75) and forced expiratory volume in 1 second (FEV1). This suggests the questionnaire accurately reflects the degree of airflow obstruction.
However, the ACQ-5’s ability to detect iSAD – a condition where the small airways in the lungs are narrowed – was limited. In fact, the study found no significant association between ACQ-5 scores and iSAD. This suggests that individuals with iSAD may experience significant airway obstruction without necessarily reporting severe symptoms that would be captured by the ACQ-5. This is a critical finding, as iSAD is increasingly recognized as a distinct asthma phenotype that may require different treatment approaches.
T2 Inflammation and the Role of Chronic Sinusitis
Approximately 48% of the study participants exhibited a T2-high inflammatory profile, characterized by elevated levels of biomarkers associated with type 2 immune responses. While increased ACQ-5 scores were associated with the T2-high phenotype, the overall ability to detect it based on symptoms alone was poor. Interestingly, the presence of chronic sinusitis was likewise independently associated with the T2-high phenotype, although this association was not statistically significant at the conventional level (P = .060). This suggests a potential link between upper airway inflammation and the underlying immune processes driving asthma.
Researchers also found that male sex was independently associated with airflow limitation, with men being 2.63 times more likely to have airflow limitation compared to women (P = .0098). This finding aligns with some previous research suggesting potential sex-based differences in asthma presentation and severity, though further investigation is needed to fully understand the underlying mechanisms.
Complementary, Not Comprehensive: The Future of Asthma Assessment
The study’s authors emphasize that these findings do not diminish the value of the ACQ-5 as a tool for monitoring symptom control. Rather, they underscore its limitations as a comprehensive diagnostic tool. “These findings do not diminish the value of the ACQ-5 as a measure of symptom control; rather, they highlight its role as a complementary, not comprehensive, assessment tool,” the researchers stated. They advocate for integrating more accessible point-of-care technologies into primary care settings to provide a more complete picture of a patient’s airway function and inflammatory status.
The retrospective, single-center design of the study and reliance on patient self-reported comorbidities are acknowledged limitations. The study also took place during the COVID-19 pandemic, which may have influenced patient access to care and symptom reporting. The relatively small sample size for the iSAD subgroup limited the statistical power to detect significant associations.
Moving forward, a more holistic approach to asthma assessment, combining patient-reported outcomes like the ACQ-5 with objective measures of lung function and biomarkers of inflammation, will be essential for tailoring treatment strategies and improving outcomes for individuals living with this complex condition. Further research is needed to explore the role of iSAD and T2 inflammation in asthma pathogenesis and to develop targeted therapies that address these specific pathways.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It’s essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have questions or comments about this story? Share your thoughts below.
Related reading
